<DOC>
	<DOCNO>NCT00766441</DOCNO>
	<brief_summary>This study ass Sitagliptin addition metformin glitazone well current sulphonylurea base treatment Ramadan . The rationale Sitagliptin offer metabolic advantage primarily low incidence hypoglycemia current sulphonylurea base treatment .</brief_summary>
	<brief_title>Sitagliptin Versus Sulphonylurea Type 2 Diabetes During Ramadan</brief_title>
	<detailed_description>To define metabolic alteration Ramadan : 1 . Primary end point : Occurrence hypoglycemia . The patient record hypoglycaemic episodes self-monitoring diary together blood glucose value . 2 . Secondary endpoint : Body weight , fast blood sugar ( FBS ) , glycosylated haemoglobin ( HbA1c ) /Fructosamine , triglyceride ( TG ) , total cholesterol ( TC ) , low-density lipoprotein-cholesterol ( LDL-C ) high density lipoprotein-cholesterol ( HDL-C ) . 3 . A subgroup undergo CGMS assessment define glycaemic excursion fast .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Muslim men woman Type 2 diabetes . 2 . Age 1878 year 3 . Intending fast month Ramadan 4 . On oral antihyperglycemic agent ( sulphonylurea based/combination therapy ) 1 . Patient hypersensitivity contraindication Sitagliptin treatment 2 . Patient CKD ( creatinine clearance &lt; 50 ml/min ) 3 . Patients participate another intervention study last 2 month 4 . Patients give inform consent 5 . Pregnant breast feed woman . 6 . Patients insulin 7 . Patients severe liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>diabetes</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>ramadan</keyword>
	<keyword>fast</keyword>
</DOC>